Homozygous C677T mutation in the MTHFR gene as an independent risk factor for multiple small-artery occlusions

Thrombosis Research

Volumn 111, Issue 1-2, 2003, Pages 39-44

  Choi, B O ^a,b   Kim, N K ^a   Kim, S H ^a   Kang, M S ^a   Lee, S ^a   Ahn, J Y ^a   Kim, O J ^a   Kim, S ^a   Oh, D ^a  

^a CHA University   (South Korea)

^b Ewha Womans University School of Medicine   (South Korea)

Author keywords

Hyperhomocysteinemia; MTHFR; Multiple small artery occlusions; Small artery occlusion

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2);

ARTERY OCCLUSION; ARTICLE; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; PRIORITY JOURNAL;

EID: 0344872775     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2003.08.022     Document Type: Article

References (35)

1. Clarke R., Daly L., Robinson K., Naughten E., Cahalane S., Fowler B., et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N. Engl. J. Med. 324:1991;1149-1155.
2. Alfthan G., Pekkanen J., Jauhiainen M., Pitkaniemi J., Karvonen M., Tuomilehto J., et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 106:1994;9-19.
3. Verhoef P., Hennekens C.H., Malinow M.R., Kok F.J., Willett W.C., Stampfer M.J. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke. 25:1994;1924-1930.
4. Perry I.J., Refsum H., Morris R.W., Ebrahim S.B., Ueland P.M., Shaper A.G. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 346:1995;1395-1398.
5. Boushey C.J., Beresford S.A., Omenn G.S., Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 274:1995;1049-1057.
6. Coull B.M., Malinow M.R., Beamer N., Sexton G., Nordt F., de Garmo P. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke. 21:1990;572-576.
7. Salooja N., Catto A., Carter A., Tudenham E.G., Grant P.J. Methylene tetrahydrofolate reductase C677T genotype and stroke. Clin. Lab. Haematol. 20:1998;357-361.
8. Harmon D.L., Doyle R.M., Meleady R., Doyle M., Shields D.C., Barry R., et al. Genetic analysis of the thermolabile mutation of 5, 10- methylenetetrahydrofolate reductase as a risk factor for ischemic stroke. Arterioscler. Thromb. Vasc. Biol. 19:1999;208-211.
9. Brattstrom L., Wilcken D.E., Ohrvik J., Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation. 98:1998;2520-2526.
10. Kelly P.J., Rosand J., Kistler J.P., Shih V.E., Silveira S., Plomaritoglou A., et al. Homocysteine, MTHFR 677C→T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology. 59:2002;529-536.
11. Faßbender K., Mielke O., Bertsch T., Nafe B., Froschen S., Hennerici M. Homocysteine in cerebral macroangiography and microangiopathy. Lancet. 353:1999;1586-1587.
12. Demuth K., Moatti N., Hanon O., Benoit M.O., Safar M., Girerd X. Opposite effects of plasma homocysteine and the methylenetetrahydrofolate reductase C677T mutation on carotid artery geometry in asymptomatic adults. Arterioscler. Thromb. Vasc. Biol. 18:1998;1838-1843.
13. Evers S., Koch H.G., Grotemeyer K.H., Lange B., Deufel T., Ringelstein E.B. Features, symptoms, and neurophysiological findings in stroke associated with hyperhomocysteinemia. Arch. Neurol. 54:1997;1276-1282.
14. Selhub J., Jacques P.F., Bostom A.G., D'Agostino R.B., Wilson P.W., Belanger A.J., et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N. Engl. J. Med. 332:1995;286-291.
15. Eikelboom J.W., Hankey G.J., Anand S.S., Lofthouse E., Staples N., Baker R.I. Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke. Stroke. 31:2000;1069-1075.
16. Markus H.S., Ali N., Swaminathan R., Sankaralingam A., Molloy J., Powell J. A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. Stroke. 28:1997;1739-1743.
17. Szolnoki Z., Somogyvari F., Kondacs A., Szabo M., Fodor L. Evaluation of the interactions of common genetic mutations in stroke subtypes. J. Neurol. 249:2002;1391-1397.
18. Roman G.C., Erkinjuntti T., Wallin A., Oantoni L., Chui H.C. Subcortical ischemic vascular dementia. Lancet Neurol. 1:2002;426-436.
19. O'Brien J.T., Erkinjuntti T., Reisberg B., Roman G., Saewada T., Pantoni L., et al. Vascular cognitive impairment. Lancet Neurol. 2:2003;89-98.
20. Vinters H.V., Ellis W.G., Zarow C., Zaias B.W., Jagust W.J., Mack W.J., et al. Neuropathologic substrates of ischemic vascular dementia. J. Neuropathol. Exp. Neurol. 59(11):2000 (Nov);931-945.
21. Jellinger K.A. The pathology of ischemic-vascular dementia: an update. J. Neurol. Sci. 203-204:2002;153-157.
22. Adams H.P. Jr., Bendixen B.H., Kappelle L.J., Biller J., Love B.B., Gordon D.L., et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 24:1993;35-41.
23. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylentetrahydrofolate reductase. Nat. Genet. 10:1995;111-113.
24. Bamford J., Sandercock P., Dennis M., Burn J., Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 337:1991;1521-1526.
25. Shimizu H., Kiyohara Y., Kato I., Tanizaki Y., Ueno H., Kimura Y., et al. Plasma homocyst(e)ine concentrations and the risk of subtypes of cerebral infarction. The Hisayama study. Cerebrovasc. Dis. 13:2002;9-15.
26. Pezzini A., Del Zotto E., Archetti S., Negrini R., Bani P., Albertini A., et al. Plasma homocysteine concentration, C677T MTHFR genotype, and 844ins68bp CBS genotype in young adults with spontaneous cervical artery dissection and atherothrombotic stroke. Stroke. 33:2002;664-669.
27. Morita H., Kurihara H., Tsubaki S., Sugiyama T., Hamada C., Kurihara Y., et al. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke in Japanese. Arterioscler. Thromb. Vasc. Biol. 18:1998;1465-1469.
28. Yoo J.H., Choi G.D., Kang S.S. Pathogenicity of thermolabile methylenetetrahydrofolate reductase for vascular dementia. Arterioscler. Thromb. Vasc. Biol. 20:2000;1921-1925.
29. Mohr J.P. Lacunes. Barnett H., Stein B., Mohr J.P., Yatsu F. Stroke pathophysiology, diagnosis and management. 1988;475-496 Churchill Livingstone, New York.
30. Rothrock J.F., Lyden P.D., Hesselink J.R., Brown J.J., Healy M.E. Brain magnetic resonance imaging in the evaluation of lacunar stroke. Stroke. 18:1987;781-786.
31. Park K.S., Podskarbi T., Yoo E.A., Shin Y.S. The C677T mutation in the methylenetetrahydrofolate reductase gene in Koreans. Korean J. Genetics. 20:1998;23-28.
32. Schneider J.A., Rees D.C., Liu Y.T., Clegg J.B. Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. Am. J. Hum. Genet. 62:1998;1258-1260.
33. Kim N.K., Kang G.D., Kim H.J., Kim S.H., Nam Y.S., Lee S., et al. Genetic polymorphisms of 5,10-methylenetetrahydrofolate reducctase (MTHFR C677T and A1298C) in healthy Korean. Korean J. Genetics. 24:2002;227-234.
34. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ. 316:1998;894-898.
35. Malinow M.R., Nieto F.J., Kruger W.D., Duell P.B., Hess D.L., et al. The effects of folic acid supplementation on plasma total homocysteine are modulated by multivitamin use and methylenetetrahydrofolate reductase genotypes. Arterioscler. Thromb. Vasc. Biol. 17:1997;1157-1162.